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Abstract
Aims: Although oxidative stress participates in the etiopathogenesis of rheumatoid arthritis, its importance in
this inflammatory disease has not been fully elucidated. In this study, we analyzed the relevance of the tran-
scription factor Nrf2, master regulator of redox homeostasis, in the effector phase of an animal model of
rheumatoid arthritis, using the transfer of serum from K/BxN transgenic mice to Nrf2-/- mice. Results: Nrf2
deficiency accelerated the incidence of arthritis, and animals showed a widespread disease affecting both front
and hind paws. Therefore, the inflammatory response was enhanced, with increased migration of leukocytes and
joint destruction in front paws. We observed an increased production of tumor necrosis factor-a, interleukin-6,
and CXCL-1 in the joint, with small changes in eicosanoid levels. Serum levels of CXCL-1 and receptor activator
for nuclear factor jB ligand were enhanced and osteocalcin decreased in arthritic Nrf2-/- mice. The expression of
cyclooxygenase-2, inducible nitric oxide synthase, and peroxynitrite in the joints was higher in Nrf2 deficiency,
whereas heme oxygenase-1 was downregulated. Innovation: Nrf2 may be a therapeutic target for arthritis.
Conclusion: Our results support a protective role of Nrf2 against joint inflammation and degeneration in ar-
thritis. Antioxid. Redox Signal. 15, 889–901.
Introduction
The transcription factor Nrf2 (NF-E2-related factor 2)controls the expression of cytoprotective genes involved
in electrophile conjugation (31, 34). Although Nrf2 is dis-
pensable for mouse development (4), this transcription factor
regulates an antioxidant defense system and its deficiency
leads to augmented oxidative stress and cytokine production
(47). Nrf2may protect against chemical carcinogenesis (2) and
cancer metastasis by the regulation of the immunological re-
sponse (41). On the contrary, the presence of high constitutive
Nrf2 levels in some tumor cells increases resistance to cancer
therapy (53). Other biological roles have been proposed for
this transcription factor, such as the control of adipocyte dif-
ferentiation (37), the modulation of hepatic lipid homeostasis
(16), or the promotion of atherogenesis (44).
Several lines of evidence have demonstrated that a defec-
tive Nrf2 activity results in greater sensitivity to oxidative and
inflammatory disorders such as asthma, pulmonary fibrosis,
neurodegeneration, colitis, and sepsis (8, 18, 23, 38, 40, 45). In
addition, Nrf2 deficiency results in a higher sensitivity to in-
flammatory responses induced by bacteria or lipopolysac-
charide. Thus, macrophages fromNrf2-/- mice generate 2-fold
higher reactive oxygen species levels after lipopolysaccharide
stimulation compared with cells from wild-type animals (25).
In particular, the enhanced production of reactive oxygen
species by NADPH oxidase could mediate the inflammatory
response induced by toll-like receptor 4 activation in Nrf2-/-
Innovation
It has been accepted that activation of Nrf2 results in
anti-inflammatory effects in different biological systems. In
contrast, knowledge on the role of this transcription factor
in rheumatoid arthritis is scarce. We have shown in the K/
BxN serum transfer model that Nrf2 deficiency results in a
widespread disease with higher production of relevant
mediators such as reactive oxygen and nitrogen species,
cytokines and chemokines, enhanced migration of in-
flammatory cells, cartilage degradation, and bone erosion.
Therefore, Nrf2 may counteract important processes in the
effector phase of arthritis to protect joint structures. Our
findings thus support that Nrf2may be a therapeutic target
for arthritis.
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mice (25). Similarly, deficiency in Nrf2 increases the inflam-
mation involved in secondary brain injury after traumatic
lesions (21) and leads to induction of angiogenic factors and
promotion of ischemia-induced neovascularization (17).
Despite the established antioxidant and anti-inflammatory
role of Nrf2, little is known about the involvement of this
transcription factor in arthritis. Previous studies have sug-
gested that Nrf2 may participate in the regulation of the im-
mune response (27) and chondrocyte integrity (13). Recently,
it has been shown that Nrf2 expression is upregulated in
rheumatoid arthritis synoviocytes compared with healthy
donors, and the deficiency in this transcription factor leads to
increased joint damage in anti-collagen II antibody-induced
arthritis (50). It has also been demonstrated that activation of
Nrf2 and induction of heme oxygenase-1 mediate the anti-
inflammatory and protective effects of cilostazol (35) and
antirheumatic gold compounds (22). These findings highlight
Nrf2 as a novel molecular target for arthritic diseases (24). In
direct contrast, it has been reported that increased expression
of Nrf2 in a subset of rheumatoid arthritis patients could lead
to a more severe disease state (46). In addition, Nrf2 may play
complex roles in articular cells as this transcription factor
mediates the expression of antioxidant genes but negatively
regulates chondrocyte and osteoblast differentiation (14, 15).
Therefore, the role of Nrf2 in arthritis remains unclear.
This studywas conducted to investigate the involvement of
Nrf2 in the effector phase of arthritis. We sought to charac-
terize the consequences of Nrf2 deficiency on key aspects of
the inflammatory response and joint lesion to gain new in-
sights into the underlying mechanisms of action. To address
this question, we used an animal model that exhibits impor-
tant features of human rheumatoid arthritis, the K/BxN se-
rum transfer model (49).
Results
Evolution of arthritis
In our experimental conditions, administration of serum
from K/BxN transgenic mice causes severe arthritis affecting
mainly hind paw joints. We have followed the progression of
arthritis in wild-type and Nrf2-/- mice. Figures 1A and 1B
show the time-course of arthritis incidence (as percentage of
arthritic animals) and the arthritic score, as well as represen-
tative pictures of paws. In wild-type mice, maximal incidence
of disease was reached on day 7 (hind paws) and 10 (front
paws). Interestingly, maximal incidence appeared earlier in
Nrf2-/- mice (day 4 in hind paws and day 7 in front paws). A
higher incidence of arthritis was observed in these animals
from days 2 to 6 in hind paws and from days 4 to 8 in front
paws, as compared with wild-type animals. As expected, ar-
thritic score values were lower in front paws of wild-type
mice compared with hind paws of the same group. In accor-
dance with the high inflammatory response present in hind
paws, Nrf2-/- andwild-typemice showed similar score values
FIG. 1. Time-course of arthritis.
(A) arthritis incidence (%) and
clinical score (mean – S.E.M) of
hind paws (n= 8 animals per
group); Nrf2-/- mice (circles), wild-
type mice (squares). Pictures of
representative hind paws taken at
the end of the experiment (day
10). (B) arthritis incidence (%) and
clinical score (mean – S.E.M) of
front paws (n= 8 animals per
group); Nrf2-/- mice (circles), wild-
type mice (squares); *p < 0.05 com-
pared to arthritic wild-type mice.
Pictures of representative front
paws taken at the end of the ex-
periment (day 10). (To see this il-
lustration in color, the reader is
referred to the web version of this
article at www.liebertonline.com/
ars).
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in both groups. In contrast, Nrf2 deficiency significantly en-
hanced the arthritic score of front paws from days 6 to 10.
Histological analysis of joint sections
In line with the results obtained for the macroscopic ar-
thritic score, the histological analysis of ankles on day 10
(Figs. 2A and 2B) revealed important inflammatory and ero-
sive changes with the presence of synovial infiltrate and ex-
udate, depletion of proteoglycan and bone erosion in both
Nrf2-/-and wild-type arthritic animals without significant
statistical differences between both groups.
The histological analysis of front joint sections at the end of
the experiment (day 10) (Figs. 3A, 3B, and 3C) indicated very
little change in the arthritic wild-type group compared with its
naı¨ve control. In contrast, the arthritic process was intense in
Nrf2-/- mice and thereforewe observed amarked infiltration of
inflammatory cells into joint tissues as well as the presence of
inflammatory exudate in the joint space. We also observed in
these animals significant increases in proteoglycan deple-
tion and bone erosion in comparison with arthritic wild-type
mice.
Levels of inflammatory mediators in serum
As shown in Table 1, no significant differences were ob-
served between naı¨ve Nrf2-/- mice and their wild-type
counterparts in constitutive levels of inflammatory mediators
on day 10. The arthritic process in wild-type animals was
accompanied by significant increases in serum IL-6, PGD2, 6-
ketoPGF1a and LTB4, whereas in Nrf2
-/- mice besides these
mediators CXCL-1, RANKL, and PGE2 were significantly
enhanced with respect to naı¨ve animals and osteocalcin de-
creased. In arthritic animals, Nrf2 deficiency increased CXCL-
1 and reduced 6-ketoPGF1a, LTB4, and osteocalcin.
Levels of inflammatory mediators in paw homogenates
In knee homogenates of day 10 (Fig. 4), we observed increases
in IL-1b, CXCL-1, PGE2, PGD2, and TXB2 after the induction of
arthritis in wild-type mice. Interestingly, the arthritic process in
FIG. 2. Histological analy-
sis of frontal sections of an-
kle joints on day 10. (A) A–H,
safranin O and fast green-
stained sections; I–P, hema-
toxylin and eosin-stained
sections. A, E, I, M, ankle joint
of naı¨ve wild-type mouse; B,
F, J, N, ankle joint of naı¨ve
Nrf2-/- mouse; C, G, K, O,
ankle joint of arthritic wild-
type mouse; D, H, L, P, ankle
joint of arthritic Nrf2-/- mouse.
C, cartilage; CA, calcaneous;
JS, joint space; S, synovium; T,
tibia. Original magnification
X40 (A–D). Original magnifi-
cation X100 (I–L). Original
magnification X200 (E–H,
M–P). (B) Histological score.
Data represent mean– S.E.M.
(n = 8 animals per arthritic
group and 4 for naı¨ve group);
***p< 0.001, **p< 0.01, *p< 0.05,
each arthritic group compared
to its respective naı¨ve group.
(To see this illustration in col-
or, the reader is referred to the
web version of this article at
www.liebertonline.com/ars).
ARTHRITIS IN NRF2 DEFICIENCY 891
the presence of Nrf2 deficiency led to the upregulation of all the
inflammatorymediators assayed. In addition, the comparison of
this group with arthritic wild-type animals showed significant
increases in TNF-a, IL-6, and CXCL-1. The levels of myeloper-
oxidase activity, a marker of neutrophils, were also determined
in knee homogenates. No significant differences were observed
between naı¨ve wild-type animals and naı¨ve Nrf2-/- mice
(6982.3–2400.7 and 5711.9–890.9 Units/g joint, respectively,
FIG. 3. Histological analysis of frontal sections of front joints on day 10. (A) Hematoxylin and eosin-stained sections. A,
E, I, front joint of naı¨ve wild-type mouse; B, F, J, front joint of naı¨ve Nrf2-/- mouse; C, G, K, front joint of arthritic wild-type
mouse; D, H, L, front joint of arthritic Nrf2-/- mouse. C, cartilage; JS, joint space; R, radius; S, synovium; U, ulna. The solid
arrows indicate areas of cell infiltration. Broken arrows (.) indicate exudate. Original magnification X40 (A–H); original
magnification X100 (I–L). (B) Safranin O and fast green-stained sections. A, E, front joint of naı¨ve wild-type mouse; B, F, front
joint of naı¨ve Nrf2-/-mouse; C, G, front joint of arthritic wild-type mouse; D, H, front joint of arthritic Nrf2-/- mouse. C,
cartilage; JS, joint space. Broken arrow indicates proteoglycan depletion from cartilage matrix (—). Original magnification
· 100 (A–D). Original magnification X200 (E–H). (C) Histological score. Data represent mean – S.E.M, n= 4; *p< 0.05 each
arthritic group compared with its respective naı¨ve group, #p< 0.05 arthritic Nrf2-/- group with respect to arthritic wild-type
group. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars).
Table 1. Levels of Inflammatory Mediators in Serum on Day 10
Naı¨ve WT Naı¨ve Nrf2-/- Arthritic WT Arthritic Nrf2-/-
TNF-a (pg/ml) 3.58 – 0.10 2.86 – 0.46 4.17 – 0.51 4.39 – 0.37
IL-6 (pg/ml) 3.53 – 0.00 3.25 – 0.86 120.6– 18.30** 193.7– 54.20**
CXCL-1 (pg/ml) 20.56– 0.78 20.52– 0.76 33.13– 4.29 52.57– 6.38**#
Osteocalcin (ng/ml) 197.97– 25.16 189.47– 8.41 141.51– 10.09* 98.92– 10.86*#
RANKL (pg/ml) 118.1– 16.58 77.95– 5.55 144.6– 20.55 125.6– 9.73*
PGE2 (ng/ml) 2.93 – 0.46 1.29 – 0.40 3.75 – 0.43 3.78 – 0.34*
PGD2 (ng/ml) 326.5– 26.88 215.2– 35.01 775.3– 74.60* 1125 – 137.6*
6-ketoPGF1a (ng/ml) 0.44 – 0.08 0.51 – 0.13 1.39 – 0.15* 0.99 – 0.08*#
LTB4 (ng/ml) 27.36– 2.49 25.15– 0.6 37.21– 1.12** 29.69– 1.30*##
WT (wild-type mice). Values are mean – S.E.M (n = 4–8); **p < 0.01, *p< 0.05 each arthritic group compared with its respective naı¨ve group,
##p < 0.01, #p < 0.05 arthritic Nrf2-/- mice with respect to arthritic wild-type animals. Mann-Whitney U-test (two-tailed).
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n=4). The induction of arthritis resulted in a significant increase
( p<0.01) in myeloperoxidase activity with respect to the corre-
sponding naı¨ve animals (23229.3–2048.0 and 22582.7–2237.0
Units/g joint, n=8, in arthritic wild-type and arthritic Nrf2-
deficient mice, respectively).
Figure 5 shows that the arthritic process in front paws in-
creased IL-1b, LTB4, PGE2, PGD2, and TXB2 in wild-type an-
imals on day 10, whereas in Nrf2-/- mice, the levels of IL-1b,
TNF-a, CXCL-1, PGE2, PGD2, and TXB2 were significantly
enhanced. The induction of arthritis in Nrf2-/- mice resulted in
higher TNF-a and lower LTB4 levels compared with arthritic
wild-type animals.
In front paws, increased myeloperoxidase activity was
observed in naı¨ve Nrf2-deficient mice with respect to naı¨ve
wild-type animals, although they did not reach statistical
significance (41582.0– 3209.0 and 19203.7 – 3898.1 Units/g
joint, n = 4, respectively). The arthritic process slightly in-
creased myeloperoxidase activity in wild-type animals
(33781.3 – 6371.5 Units/g joint, n= 8, with respect to naı¨ve
wild-type mice). Interestingly, arthritic Nrf2-deficient mice
showed a dramatic increase with values of 88690.2– 4838.6
Units/g joint, n = 8, p < 0.001 with respect to naı¨ve Nrf2-defi-
cient mice and also to arthritic wild-type animals.
HO-1 and COX-2 protein expression
in paw homogenates
We studied the expression of HO-1, a target of Nrf2, in paw
homogenates of day 10. As shown in Figures 6A and B, there
is a low level of HO-1 in naı¨ve animals and Nrf2 deficiency
does not modify the constitutive expression of this protein. In
arthritic animals, HO-1 protein was induced in both front
paws and knees and this induction was decreased in Nrf2-/-
mice. We also determined the expression of COX-2 in paw
homogenates. Although no significant differences were ob-
served between both groups of naı¨ve animals, the induction of
arthritis enhanced COX-2 expression in front paws and knees,
and this expression was increased in Nrf2-/- mice compared
with wild-type animals, with statistical significance in front
paws.
Immunohistochemical analysis of iNOS
expression in joint sections
No significant iNOS positive cells were observed in naı¨ve
animals in joint sections of day 10. In contrast, iNOS was in-
duced in the joint during the inflammatory process mainly in
chondrocytes of ankles (Fig. 7A). In addition, iNOS induction
FIG. 4. Levels of inflammatory mediators in hind paw (knees) homogenates on day 10. Data represent mean – S.E.M,
n = 4–8; ***p < 0.001, **p < 0.01, *p< 0.05 each arthritic group compared with its respective naı¨ve group, ##p< 0.01, #p < 0.05
arthritic Nrf2-/- group with respect to arthritic wild-type group.
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was significantly higher in front paws of arthritic Nrf2-/- mice
with respect to arthritic wild-type animals (Fig. 7B).
Immunohistochemical analysis
of nitrotyrosine expression in joint sections
Constitutive nitrotyrosine immunostaining was detected
mainly in Nrf2-deficient mice in both ankles and front paw
joints on day 10 (Figs. 8A and B), whereas the induction of
arthritis increased nitrotyrosine expression that was apparent
in chondrocytes, synovium, and infiltrate. We observed in
arthritic animals that nitrotyrosine expression was enhanced
in Nrf2-/- mice compared to their wild-type counterparts with
statistical significance in front paws.
Discussion
K/BxN serum transfer to healthy mice leads to an auto-
immune and inflammatory response mediated by IgG1 au-
toantibodies (28, 30). This animal model of arthritis exhibits
clinical similarities to human rheumatoid arthritis, with cell
infiltration, synovitis, pannus formation, and erosion of car-
tilage and bone (49). The K/BxN serum transfer model em-
ulates rheumatoid arthritis specificity as there is a joint-
specific inflammation that may be dependent on autoantigen
binding to cartilage surface (43). In this study, the induction of
arthritis in naı¨vemice slightly increased neutrophil migration,
an essential process to initiate and maintain arthritis (49), in
front paws, but its effect in hind paws was strong. Of note,
Nrf2 deficiency dramatically upregulated neutrophil migra-
tion in front paws. Therefore, maximal severity of arthritis
was observed in hind paws of wild-type animals, limiting a
further increase in inflammation in the presence of Nrf2 de-
ficiency. In contrast, front paws exhibited a low-grade in-
flammation after induction of arthritis in wild-type animals
that was significantly enhanced in Nrf2-/- mice. Interestingly,
our data have revealed that Nrf2 deficiency accelerates the
incidence of arthritis in this experimental model and leads to a
widespread disease, with important inflammation and lesions
in both hind and front joints.
Induction of HO-1 during inflammatory conditions could
be part of an adaptive mechanism to limit cytotoxicity via
scavenging of reactive oxygen or nitrogen species, regulation
of cell proliferation, and prevention of apoptosis (reviewed in
(1)). We have shown previously that induction of HO-1 can
exert partial anti-arthritic effects (9). In the present study, Nrf2
deficiency during K/BxN serum transfer arthritis led to in-
creased iNOS expression and production of reactive oxygen
and nitrogen species, whereas the expression of HO-1 was
downregulated. Our results thus suggest that the increased
production of oxidative stress due to Nrf2 deficiency may
FIG. 5. Levels of inflammatory mediators in front paw homogenates on day 10. Data represent mean – S.E.M, n = 4–8;
***p< 0.001, **p< 0.01, *p< 0.05 each arthritic group compared with its respective naı¨ve group, ###p < 0.001, #p< 0.05 arthritic
Nrf2-/- group with respect to arthritic wild-type group.
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mediate an enhanced inflammatory response and joint lesion
in the K/BxN serum transfer model of arthritis which is in line
with data from anti-collagen II antibody-induced arthritis
(50).
Increased eicosanoid production has been shown to con-
tribute to the development of arthritis in human patients and
animal models (5). There are differences in the eicosanoid
profile according to the experimental model, as it has been
reported a more relevant role for COX-1 and PGI2 compared
to COX-2 and PGE2 in the K/BxN serum transfer arthritis (5).
In addition, our previous research suggests the participation
of another prostanoid pathway, PGD2, in the effector phase of
this arthritis model (29). Joint inflammation is dependent on
neutrophil recruitment via LTB4 (6) which also stimulates
synovial fibroblasts migration and invasion (7). In this study,
the PGI2 metabolite 6-ketoPGF1a, PGD2, and LTB4 were sig-
nificantly increased in the serum of arthritic wild-typemice on
day 10, compared with naı¨ve animals, whereas the small in-
crease in PGE2 was not significant. The levels of these eicos-
anoids and TXB2 were also enhanced in the joints at that time
point. In Nrf2 deficiency, the arthritic process significantly
induced the production of eicosanoids, although the effect on
LTB4 wasweak and the production of serum 6-ketoPGF1a and
LTB4 in Nrf2-deficient mice was lower than in wild-type an-
imals. These observations suggest the participation of Nrf2 in
the modulation of eicosanoid synthesis and/or metabolism
during inflammation. Little is known about the possible
modification by this transcription factor of the expression or
activity of enzymes involved in eicosanoid pathways. In our
study, Nrf2 deficiency resulted in increased COX-2 expression
in paws, which is in line with reports in ischemia-induced
neovascularization (17). The regulation of enzymes involved
in eicosanoid pathways is very complex in vivo. Although the
Nrf2 enhancer element is present in thromboxane synthetase,
different trans-activating factors may confer cell-type prefer-
ential expression (52). On the other hand, in situations of ox-
idative stress, PGD2 and cyclopentenone isoprostanes can be
generated in a nonenzymatic manner (11) and therefore, this
mechanism may contribute to the increased serum levels of
this prostaglandin in arthritic Nrf2-/- animals which have a
reduced antioxidant defense system. Interestingly, our data
indicate that Nrf2 deficiency results in a higher migration of
FIG. 6. Western blot analysis of HO-1 and COX-2 protein. (A) Hind paws (knees) homogenates; (B) front paws ho-
mogenates. GAPDH was used as a control. Relative expression of HO-1/COX-2 and GAPDH bands was calculated after
densitometric analysis of samples. Data represent mean– S.E.M, n= 3; **p< 0.01, *p< 0.05 each arthritic group compared with
its respective naı¨ve group, ##p< 0.01, #p< 0.05 arthritic Nrf2-/- with respect to arthritic wild-type group.
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pro-inflammatory cells into the joints during the development
of arthritis, whichmay be dependent on several inflammatory
mediators.
Pro-inflammatory cytokines and chemokines play an im-
portant role in the effector phase of experimental arthritis. The
arthritic process is associated with the increase of cytokines
such as IL-1b, TNF-a, and IL-6, which are highly expressed in
the joints of rheumatoid arthritis patients (10). In particular,
experimental data support the view that TNF-a plays an im-
portant role in rheumatoid arthritis (48). Our results have
shown an upregulation of cytokine expression during arthritis
in Nrf2-deficient animals. Therefore, we observed significant
differences in TNF-a and IL-6 levels with respect to wild-type
animals. This is in line with recent reports indicating a higher
infiltration of inflammatory cells into skeletal muscle and
higher levels of TNF-a mRNA in Nrf2-deficient animals fol-
lowing ischemia (17). Similarly, pulmonary inflammation
induced by lipopolysaccharide was enhanced in Nrf2-/- mice
with increased mRNA expression of IL-6 in the lungs (25).
Pro-inflammatory cytokines inhibit bone formation and
stimulate osteoblasts to produce RANKL leading to osteoclast
activation and bone resorption (reviewed in (3)). In this study,
the arthritic process resulted in enhanced serum levels of
RANKL in the presence of Nrf2 deficiency whereas osteo-
calcin levels were significantly decreased. Therefore our data
suggest that increased bone resorption and reduced bone
formation contribute to arthritic changes in these animals and
Nrf2 may be a protective factor for bone metabolism in the
presence of inflammation.
It is known that oxidative stress can induce chemokine ex-
pression during inflammatory responses and thus activation of
Nrf2 and induction of target genes such as HO-1 would inhibit
chemokine production, as reported for IL-8 in HT-29 cells (26).
Nevertheless, the role of Nrf2 may be more complex and in
FIG. 7. Immunohistochemical analysis of iNOS in joints on day 10. (A) Ankle joint sections, (B) front joint sections. A, E, I,
joint of naı¨ve wild-type mouse; B, F, J, joint of naı¨ve Nrf2-/- mouse; C, G, K, joint of arthritic wild-type mouse; D, H, L, joint
of arthritic Nrf2-/- mouse. C, cartilage; CA, calcaneous; JS, joint space; S, synovium; T, tibia. A–H sections were treated with a
specific anti-iNOS antibody whereas I–L sections were treated with rabbit IgG control. Original magnification X100 A (A–D).
Original magnification X200 A (E–L), B (A–D, I–L). Original magnification X400 B (E–H). Data represent mean – S.E.M, n=
4–8; **p < 0.01, *p < 0.05 each arthritic group compared with its respective naı¨ve group, #p< 0.05 arthritic Nrf2-/- group with
respect to arthritic wild-type group. (To see this illustration in color, the reader is referred to the web version of this article at
www.liebertonline.com/ars).
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some cell types the activation of this transcription factor has
been related to IL-8 mRNA stabilization (54). Chemokines are
also upregulated in inflamed joints during K/BxN serum
transfer arthritis and could mediate neutrophil recruitment to
the joints. Gene expression of CXCL1 is upregulated in ankles
and synovial fluid in parallelwith the progression of arthritis in
this experimental model (20). This chemokine is a ligand of
CXCR2 mediating the migration of different cell types during
inflammatory conditions (39, 42). Recent studies have dem-
onstrated that CXCR2 signaling is critical for K/BxN serum
transfer arthritis (20). It is interesting to note that CXCL-1 in-
duction during the arthritic process is augmented by Nrf2 de-
ficiency, which may play an important role in the potentiation
of the inflammatory response observed in these animals.
MCP-1 is another inflammatory mediator upregulated
during arthritis (20, 33). This chemokine enhances migration
and proliferation of synovial fibroblasts as well as matrix
metalloproteinase expression (12). Nevertheless, the influence
of MCP-1 upregulation on arthritis progression is not clear, as
recent studies using CCL2-deficient mice have shown no
differences in disease severity with respect to wild-type ani-
mals in the K/BxN serum transfer model (20). Our data in-
dicate that Nrf2 deficiency in arthritic animals results in the
upregulation of MCP-1 in hind paws which is consistent with
results in muscle ischemia and pulmonary inflammation (17,
25). It is known that MCP-1 promoter activation depends on
nuclear factor jB activity that responds to reactive oxygen
species (51) and therefore increased oxidative stress in Nrf2
deficiency would facilitate MCP-1 synthesis.
In conclusion, our study provides novel insights into the
role of Nrf2 in the inflammatory response in vivo. Taken to-
gether, our data suggest that Nrf2 acts upon the production of
inflammatory mediators to modulate the systemic and local
processes driving erosive arthritis.
FIG. 8. Immunohistochemical analysis of nitrotyrosine in joints on day 10. (A) Ankle joint sections, (B) front joint
sections. A, E, I, joint of naı¨ve wild-type mouse; B, F, J, joint of naı¨ve Nrf2-/- mouse; C, G, K, joint of arthritic wild-type
mouse; D, H, L, joint of arthritic Nrf2-/-mouse. C, cartilage; CA, calcaneous; JS, joint space; T, tibia. A–H sections were treated
with a specific anti-nitrotyrosine antibody whereas I–L were treated with rabbit IgG control. Original magnification X200 (A–
D, I–L). Original magnification X400 (E–H). Data represent mean– S.E.M, n= 4–8; **p< 0.01, *p< 0.05 each arthritic group
compared with its respective naı¨ve group, #p < 0.05 arthritic Nrf2-/- group with respect to arthritic wild-type group. (To see
this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars).
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Materials and Methods
Induction of arthritis
K/BxN mice were generated by crossing KRN-TCR-
transgenic mice (B10.BR genetic background) with NOD
mice. The C57BL/6J Nrf2 knockout mice were kindly pro-
vided by Dr. Masayuki Yamamoto (University of Tsukuba,
Japan) (19). These mice exhibit a normal phenotype and life-
span, but are hypersensitive to treatments that lead to oxi-
dative or inflammatory stress. For instance, these animals
exhibit exacerbated neuron death, gliosis, and neuroin-
flammation after treatment with the parkinsonian toxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (40) or lipopoly-
saccharide (18).
Genotyping of wild-type (Nrf2 + / + ) C57BL/6J mice and
Nrf2-deficient (Nrf2-/-) littermates was done as reported
previously (19). Arthritis was induced in 16–24-week-old
mice by intraperitoneal injection of 150 ll serum from ar-
thritic K/BxNmice on day 0 and 2. All mice weremaintained
in cages with a 12-hour light/dark cycle and free access to
standard diet and water. Mice were housed and cared for by
the veterinary staff in accredited facilities andwere routinely
screened for health status. Mice were assigned to their ex-
perimental group (n = 8 in arthritic wild-type and arthritic
Nrf2-/- groups, n = 4 in naı¨ve wild-type and naı¨ve Nrf2-/-
groups). Blood was collected from the retro-orbital venous
plexus on day 10, and animals were then sacrificed by cer-
vical dislocation. Hind and front paws from randomly se-
lected animals in each group were isolated for histological
and immunohistochemical analyses (8 ankles and 4 front
paws in arthritic groups, 4 ankles and 4 front paws in naı¨ve
groups) and the rest of them were used for measurement of
inflammatory markers. All studies were performed in ac-
cordance with European Union regulations for the handling
and use of laboratory animals. The protocols were approved
by the institutional Animal Care and Use Committees
(University of Valencia and Autonomous University of
Madrid, Spain).
Arthritis score
Joint inflammation was scored visually in each paw. The
clinical severity of arthritis was graded using a scale of 0–2 for
each paw where 0 =uninflamed, 1 =mild, 1.5 =marked, and
2 = severe inflammation. Scoring was performed by two in-
dependent observers without knowledge of the experimental
groups.
Measurement of inflammatory mediators in serum
To determine the levels of prostaglandin(PG)D2 and 6-
ketoPGF1a in serum samples, ELISA kits were used (Cay-
man Chemical, Ann Arbor, MI) with a range of detection of
78–10000 and 1.6–1000 pg/ml, respectively. PGE2 and leu-
kotriene B4 (LTB4) levels were measured by radioimmu-
noassay (32). CXCL-1 was determined by ELISA
(Promokine, PromoCell GmbH, Heidelberg, Germany, 8–
1000 pg/ml). The levels of tumor necrosis factor a (TNF-a),
interleukin(IL)-6, osteocalcin, and receptor activator for
nuclear factor jB ligand (RANKL) in serum were deter-
mined by the LINCOplex system (Millipore Iberica, Ma-
drid, Spain), with sensitivity of 0.8, 0.6, 7.0, and 3.3 pg/ml,
respectively.
Measurement of inflammatory mediators
in paw homogenate
Hind paws (knees) and front paws were amputated, ho-
mogenized in liquid N2 with 1ml of A buffer pH 7.46 (10mM
HEPES, pH 8, 1mM EDTA, 1mM EGTA, 10mM KCl, 1mM
dithiothreitol, 5mM NaF, 1mM Na3VO4, 1lg/ml leupeptin,
0.1 lg/ml aprotinine, and 0.5mM phenylmethyl sulfonyl
fluoride). The tissue homogenates obtained were sonicated
(10 sec three times at 20% with a 10-sec incubation on ice be-
tween bursts) in an ultrasonic processor (VC130PB, Sonics &
Materials Inc., Newtown, CT) and centrifuged at 1200 g,
10min at 4C. Supernatants were removed and used for de-
termination of eicosanoid, cytokine, and chemokine levels.
TNF-a and IL-1b were determined by ELISA (R&D Systems
Inc., Minneapolis, MN, with a range of detection of 32–2700
and 25–2000pg/ml, respectively). IL-6 and monocyte che-
moattractant protein-1 (MCP-1) were measured using the
ELISA kits from eBioscience Inc. (San Diego, CA), with sen-
sitivity of 2 and 7 pg/ml, respectively. CXCL-1 and PGD2
were determined by ELISA, as indicated above, and PGE2,
thromboxane B2 (TXB2) and LTB4 were quantified by radio-
immunoassay (32). Myeloperoxidase activity was assayed as
described previously (36).
Histological analysis
For standard histological assessment, isolated ankles and
front pawswere kept in 10% formalin for 4 days, decalcified in
5% formic acid, and subsequently dehydrated and embedded
in paraffin. Standard frontal sections (7 lm) of the joint tissue
were mounted on SuperFrost slides (Menzel-Gla¨ser,
Braunschweig, Germany). Hematoxylin and eosin staining
was performed to study joint inflammation. The severity
of inflammation in the joints was scored on a scale of 0–3
(0 =no cells, 1=mild cellularity, 2=moderate cellularity, and
3 =maximal cellularity). To study proteoglycan depletion
from the cartilage matrix, sections were stained with safranin
O, followed by counterstaining with fast green. Depletion of
proteoglycan was determined using an arbitrary scale of 0–3,
ranging from normal, fully stained cartilage to destained
cartilage that was fully depleted of proteoglycan. Bone de-
struction was graded on a scale of 0–3, ranging from no
damage to the complete loss of bone structure. Chondrocyte
death was scored on a scale of 0–3, where 0 =no empty lacu-
nae and 3= complete loss of chondrocytes from the cartilage
layer. Cartilage surface erosion was scored on a scale of 0–3,
where 0 =no cartilage loss and 3= complete loss of articular
cartilage. Histopathologic changes were scored on three
semiserial sections of the joint, with sections spaced 70lm
apart. Scoring was performed in a blind manner by two in-
dependent observers.
Immunohistochemistry
For immunohistochemical analyses, isolated ankles and
front paws were fixed for 4 days in 10% formalin, decalcified
in EDTA (10%), and subsequently dehydrated and embedded
in paraffin. Tissue sections (7 lm) were deparaffinized, rehy-
drated, and treated with 2% H2O2 for 10min at room tem-
perature. Sections were incubated for 15min with goat
antiserum (1:10), and thereafter incubated for 2 h with rabbit
anti-mouse antibodies against inducible nitric oxide synthase
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(iNOS) or nitrotyrosine (22036a and 10189540, respectively;
Cayman Chemical). Rabbit IgG antibody (Dako, Glostrup,
Denmark) was used as control. After rinsing, sections were
incubated for 30min with the secondary biotinylated anti-
body: swine anti-rabbit antibody (Dako), and processed using
streptavidin–horseradish peroxidase (Dako). Development of
the peroxidase staining was performed with diaminobenzi-
dine (Sigma-Aldrich, St Louis, MO). Sections were counter-
stained with hematoxylin for 1min. Positive cells were
evaluated in the joint cartilage (tibia-calcaneous in two
semiserial sections of the ankle and radius in two semiserial
sections of the front paw) by two independent observers.
Western blot analysis
Supernatants from paw homogenates (knees and front
paws) were sonicated (10 sec twice at 20% with a 10-sec in-
cubation on ice between bursts) in an ultrasonic processor
(VC130PB, Sonics &Materials Inc.) and centrifuged at 10,000 g
for 15min at 4C. The new supernatants were used to assess
heme oxygenase-1 (HO-1) and cyclooxygenase (COX)-2 pro-
tein expression. Equal amounts of proteinwere loaded on 10%
SDS-PAGE and transferred onto polyvinylidene difluoride
Hybond-P membranes (GE Healthcare, Barcelona, Spain) for
120min at 125mA. Membranes were blocked in phosphate-
buffered saline (0.02 M, pH 7.0)-Tween 20 (0.1%) containing
4% w/v unfatted milk, and incubated with a specific poly-
clonal antibody against HO-1 (1/1000) (SPA-896, Stressgen,
Victoria, British Columbia, Canada), COX-2 (1/1000) (160116,
Cayman Chemical) or glyceraldehyde 3-phosphate dehydro-
genase (GAPDH, 1/10000) (G9545, Sigma-Aldrich). Finally,
blots were washed and membranes were incubated with
peroxidase-conjugated goat anti-rabbit IgG (1/5000, Dako).
The immunoreactive bands were visualized using an en-
hanced chemiluminescence system (ECLTM Western Blotting
Detection reagents, GE Healthcare). Images were captured
with the AutoChemi image analyzer (UVP Inc., Upland, CA)
and protein band densitometry was performed.
Statistical analysis
Differences between experimental groups were tested us-
ing the two-tailed Mann-Whitney U test. P values less than
0.05 were considered significant
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